Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Wed · 7 Oct · today
Thu · 8 Oct
Fri · 28 Aug
partnership
Teva announced a proposed acquisition of a novel neuroscience product under its Pivot to Growth strategy. A same-day release from BioXcel Therapeutics announcing an asset sale agreement with Teva Pharmaceuticals identifies the counterparty. Deal terms are not stated in the headline and are not reproduced here.
Markets open original ↗
product
Roche reported that Vabysmo demonstrated sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration. This is follow-up data on an already-approved product, so it is graded as incremental.
Markets open original ↗
Thu · 27 Aug
earnings
Canadian Solar reported a Q2 2026 loss of $1.40 per share versus a consensus estimate of a $1.01 loss and a year-ago loss of $0.08. Revenue of $1.21 billion topped the $1.17 billion consensus but fell 28.7% from $1.69 billion a year earlier, and solar modules recognized as revenue totaled 3.1 gigawatts, down 25% year over year. The company guided Q3 revenue to $1.30-$1.50 billion with gross margin of 13.5%-15.5%, below the $1.65 billion Q3 consensus cited in the article.
Markets open original ↗
product
RTX's Raytheon business completed a $50 million, 17,000 square-foot expansion of its Forest, Mississippi plant, bringing the site to 445,000 square feet of manufacturing space. The facility builds electronic warfare and radar systems including Next Generation Jammer Mid-Band pods for the U.S. Navy and the Australian government, and the expansion is expected to add 100 high-skill positions by 2028.
Markets open original ↗
partnership
argenx announced it has completed its acquisition of Forte Biosciences, Inc. Forte is not in this universe, so it is not listed as a counterparty. Consideration is not stated in the headline and is not reproduced here.
Markets open original ↗
